AI assistant
Jade Biosciences, Inc. — Director's Dealing 2021
Jul 2, 2021
33383_dirs_2021-07-01_1b3a0a08-d74f-44c7-98b6-0856c2a2049c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aerovate Therapeutics, Inc. (AVTE)
CIK: 0001798749
Period of Report: 2021-06-29
Reporting Person: Resnick Joshua (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-29 | Stock Option (Right to Buy) | $14.00 | A | 25000 | Acquired | 2031-06-28 | Common Stock (25000) | Direct |
Footnotes
F1: This option shall vest in 36 substantially equal monthly installments, with the first installment vesting on July 29, 2021.
F2: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.